The SERPINB2 gene is strongly upregulated in inflammatory states. In monocytes, it can constitute up to 1% of total cellular protein. It functions in protection from proteotoxic stress and plays a role in angioedema. The purpose of this study was to define the roles of enhancer RNAs embedded in the SERPIN gene complex. We found that the upstream enhancer RNAs upregulated SERPINB2 and the enhancer RNAs were expressed prior to those of SERPINB2 mRNA. Studies of the SERPINB2 promoter demonstrated the presence of an RNA polymerase II pause-inducing protein, NELF. Stimulation with LPS led to recruitment of the pause-releasing kinase P-TEFb and departure of the pause-inducing protein NELF. RNA immunoprecipitation revealed that NELF and the CDK9 component of P-TEFb bound to the enhancer RNAs after stimulation with distinct kinetics. Knock-down of the enhancer RNAs compromised stimulus induction of promoter and enhancer chromatin changes. Conversely, over-expression was associated with enhanced recruitment of c-JUN and increased expression of SERPINB2 mRNA expression. This study is the first to associate enhancer RNAs with SERPINB2 and is the first demonstration of acquisition of NELF binding by enhancer RNAs on chromatin.
Introduction
SERPINB2 has been identified as the gene most highly upregulated in inflammatory bowel disease (Burczynski et al., 2006; Miao et al., 2013) . We also identified it as upregulated in systemic lupus erythematosus (SLE) (Shi et al., 2014) . It is expressed in keratinocytes, monocytes, placenta, and adipocytes (Kruithof et al., 1995; Lijnen et al., 2007) and is one of the most highly inducible genes in monocytes. It can comprise up to 1% of total cellular protein in monocytes (Darnell et al., 2006; Ritchie et al., 1995) . Recent data have implicated SERPINB2, also known as PAI-2 (plasminogen activator inhibitor-2), in type III angioedema and a new functional analysis revealed one of its key functions is to modulate proteotoxic stress (Lee et al., 2015; Joseph et al., 2016) .
In spite of its highly dynamic expression, little is known about its regulation. SERPINB2 has been implicated in Th2 responses where it is regulated by STAT6 (Shea-Donohue et al., 2014) . Other recognized transcriptional regulators include NFκB, AP-1 and C/EBPβ (Park et al., 2005; Udofa et al., 2013) . Histone deacetylase inhibitors modulate SERPINB2 expression but the epigenetic control of expression has not been previously investigated (Foltz et al., 2006) . Investigation of epigenetic regulation is critical given the aberrant expression of SERPINB2 in many human disease states and its highly dynamic expression.
We identified a complex of non-coding RNAs (ncRNAs) within the SERPIN gene cluster on chromosome 18. These ncRNAs overlapped with known enhancer chromatin marks and we therefore investigated their role in the regulation of SERPIN family members in the vicinity. Enhancers represent regulatory regions capable of acting on promoters at a distance and recent evidence has demonstrated that enhancer RNAs (eRNAs) participate in chromatin looping that activates gene transcription (Kagey et al., 2010; Li et al., 2013) .
Most inducible genes are regulated at the level of pause-release and elongation (Core et al., 2008; Guenther et al., 2007; Min et al., 2011; Gilchrist et al., 2008; Nechaev and Adelman, 2008) . Paused RNAPII is held in place by negative elongation factor (NELF), Gdown1, and DRBsensitivity inducing factor (DSIF) (Wada et al., 1998a; Yamaguchi et al., 1999; Cheng et al., 2012) . Release from pausing requires recruitment of positive transcription elongation factor-b (P-TEFb), a complex of cyclindependent kinase 9 (CDK9) and cyclin T1. P-TEFb is typically seques-tered in an inactive complex with 7SK snRNP, Hexim1, and MePCE proteins (Yik et al., 2003; Michels et al., 2003) . To escape pausing, BRD4 recruits P-TEFb by binding to acetylated histones (Rahman et al., 2011; Dey et al., 2003) . The mechanism by which P-TEFb is liberated from the 7SK complex is not completely understood but appears to involve several pathways (Chen et al., 2008; Contreras et al., 2007; Fujinaga et al., 2012) . The eRNAs may induce release of NELF from RNAPII (Schaukowitch et al., 2014) , thereby linking enhancer function and pause −release of RNAPII. There have been few studies examining eRNA interactions with pause-release proteins at enhancers and promoters.
We chose to investigate the interaction of eRNAs at the promoter of the SERPIN complex because it offers a unique opportunity to compare related but divergently regulated genes. Recognition of regulatory facets of ncRNAs and their interactions with transcriptional regulatory proteins has been increasing (Sigova et al., 2015) . A novel finding is the interaction of CDK9 and NELF with the eRNAs.
Materials and methods

Cells, transfections and reagents
Primary monocytes from healthy human donors were obtained from the Center for AIDS Research Core Facility at the University of Pennsylvania under an IRB approved protocol. They were purified by elutriation and adherence and were more than 90% pure by flow cytometry. The SLE samples reported in Fig. 1 were obtained as part of a previously reported study under a separate IRB-approved protocol Zhang et al., 2015) . MonoMac6 cells were used as a monocyte cell line, and K562 was used as an early hematopoietic stem cell line. Both were maintained in RPMI with 10% cosmic calf serum (with OPI supplement (Sigma-Aldrich, St. Louis, MO) for MonoMac6 cells). MonoMac6 cells were obtained from the German source and thawed from the original source vials every 2-3 months. K562 was obtained from ATCC and the phenotype was validated periodically by flow cytometry. HEK293 cells were cultured in DMEM with 10% cosmic calf serum and were obtained from ATCC and thawed fresh for these experiments. The SLE patient RNA samples have been previously reported (Shi et al., 2014; Shi et al., 2015) , although these analyses are new. Transfection of cells was performed by electroporation with the Amaxa Cell Line Lonza Nucleofector Kit (Amaxa Biosystems, Gaithersburg, MD) or Lipofectamine 2000 (ThermoFisher, Waltham, MA). HPLC-purified LPS and phorbol myristate acetate (PMA) were purchased from Sigma-Aldrich (St. Louis, MO).
For knock-down assays, 2 million cells were transfected with 500 nM antisense oligonucleotide using nucleofection. For over-expression, 2 million cells were transfected with 5 μg plasmid using nucleofection. LPS treatment utilized 1 μg for one hour unless otherwise specified. Each assay was performed using three separate experiments minimally.
5,6-Dichloro-1-β -D-ribofuranosy Benzimidazole (DRB) is a CDK9 inhibitor from Sigma-Aldrich. The iBET (Life science Research, Billerica, Massachusetts) inhibitors targets bromodomains. C646 (Santa Cruz, Dallas, Texas) is an inhibitor of dynamic histone acetyla- (Bernstein et al., 2012) data indicated that these ncRNAs are located within active enhancer regions, termed Enhancer 1 and Enhancer 2. The eRNAs described in the text are listed above the tracks. (B) The sequencing depth of H3K4me3 at the SERPINB2 gene is displayed from a previously published dataset Zhang et al., 2016) . The depth is the normalized average of 6 control or 6 SLE samples. The plotted data is in log2 scale. The magenta color indicates the overlap, with pink and blue representing the mean for SLE and control, respectively. H3K4me3 is higher in SLE patients at SERPINB2 both upstream and downstream of the transcription start site (0). (C) Quantitative RT-PCR was used to measure the difference of SERPINB2 mRNA level in 15 SLE patient monocyte samples and 13 healthy control monocyte samples. The RNA samples came from a previously published cohort (Shi et al., 2014) . SERPINB2 mRNA levels are significantly higher (**** p < 0.0001). Results were normalized to 18S expression. Knock-down Antisense oligo 774ASO 5′-A*G*A* A*A*C* T*C*C* C*T*T* G*C*C* A*C*C* C*A −3 775ASO1 5′-G*G*T* T*T*G* C*A*G* G*T*C* C*C*A* G*G*T* T*C-3′ 775ASO2 5′-G*T*G*C*C*C*G*C*T*T*T*C*C*T*A*C*T*C*A*G*T-3′
RNA immunoprecipitation and ChIP assays
The RNA immunoprecipitation (RNA-IP) assay was modified as described by Niranjanakumari (Niranjanakumari et al., 2002) and Chand (Chand et al., 2014) . Briefly, 20-40 million cells were crosslinked using 1% formaldehyde for 10 min and quenched with glycine. The fixed cells were lysed in RIPA buffer (1%NP40, 0.5% sodium deoxycholate, 0.05%SDS, 1 mM EDTA, 150 mM NaCl) and sonicated. The precleared lysates were incubated with antibodies and protein A agarose at 4°C. Immune complexes were washed and reverse crosslinked. Direct-zol™ RNA MiniPrep Kit was used to extract the immunoprecipitated RNA. Chromatin immunoprecipitation assay (ChIP) experiments were performed as previously described (Lee et al., 2003; Garrett et al., 2008) . The antibodies to CDK9 (C-20), c-JUN (H-79) and NELF-A (A-20) were from Santa Cruz Biotechnology (Santa Cruz, CA). The antibodies to H3K4me3 and H3K27ac were from Active Motif (Carlsbad, CA). Antibodies to H3K4me1 and H3K4me2 were from Millipore (Darmstadt, Germany). GST (Invitrogen, Camarillo, CA) or IgG (Cell Signaling, Boston, MA) were used as negative control antibodies. Signals are reported as units normalized to 10% input according to the formula 2^(10%input CT-Sample CT).
Luciferase reporter assay
The pGL3-TK vector and the TK-A7 positive control were gifts from the Shiekhattar lab and used to test enhancer function by transient transfection (Orom et al., 2010) . The TK-A7 control regulates the UBE2VI gene. The inserts were amplified from genomic DNA and subcloned into the BamHI and SalI sites. HEK 293 and K562 cells were transfected with Lipofectamine 2000 (Invitrogen). The luciferase assay was performed in 96-well white plates using the Dual-Luciferase reporter assay kit (Promega, Madison, WI) according to the manufacturer's protocol. 5 × 10 4 cells were transfected with 0.2 μg of plasmid and 0.01 μg pRL renilla reporter vector. Luciferase and renilla signals were measured at 24 h.
Theory
Pause-release of RNAPII appears to be a key regulatory mechanism particularly for genes involved in inflammatory responses (Core et al., 2008; Min et al., 2011) . NELF and CDK9 (P-TEFb) are known to regulate RNAPII pausing. This study examined pause-release at two related genes that are divergently regulated and specifically examined interactions of eRNAs with the pause release machinery. eRNA behaviors with pause release proteins have been infrequently examined and our study addressed a major knowledge gap in a biologically relevant system.
Results
Non-coding RNA and mRNA expression
The rationale for this study builds on an observation made using monocytes from patients with systemic lupus erythematosus (SLE). A cluster of RNAs, not previously annotated, was found approximately 21 kb upstream of the SERPINB2 gene in SLE monocytes (Shi et al., 2014) . Very low levels were seen in control monocytes. We subsequently identified that the ncRNAs were inducible with LPS. These RNAs did not appear to be translatable except as small peptides and were considered to be ncRNAs. Near the SERPINB2 locus were other Clade B SERPIN family members, SERPINB3, SERPINB4, SERPINB8, SERPINB10, SERPINB7 and SERPINB11. SERPINB2 was the closest gene to the identified ncRNAs and the 3′ end of the SERPINB7 gene was 50 kb upstream of SERPINB2 and the first exon of SERPINB10 was downstream of SERPINB2 (Fig. 1A) . The RNAs (772, 774, 775) formed a cluster near an enhancer, defined by H3K27ac in UCSC Genome Browser. 774 is centered on the H3K27ac peak, 775 is at the proximal edge of the H3K27ac peak and 772 is at the distal shores of the H3K27ac peak. We will refer to this region as Enhancer 1. Examination of UCSC Genome Browser revealed limited tissue expression of the eRNAs. Using the criteria of H3K27ac peaks, a second enhancer (Enhancer 2) was found just 8 kb upstream of the SERPINB2 promoter. Another ncRNA (571) was found 4 kb upstream of the transcription start site of SERPINB2 and was not embedded in enhancer-like chromatin.
We hypothesized that the RNAs participated in the regulation of the highly inducible SERPINB2 gene. To determine whether chromatin alterations were also found at this locus in this inflammatory disease, we examined H3K4me3 at the SERPINB2 promoter using previously generated ChIP-seq data on patients with SLE. We found higher H3K4me3 both downstream and upstream of the transcription start site in SLE patients (Fig. 1B) . Additionally, mRNA for SERPINB2 was The firefly luciferase vectors were co-transfected with a constitutive Renilla control pRL-TK into HEK293 cell or K562 cells. Construct 172 is a negative control, which is an LPSinduced non-coding RNA but not an eRNA and not located in the SERPIN locus. PGL3-TK-A7 is a positive ncRNA enhancer control from near the UBE2VI gene (48). Inducible firefly luciferase was normalized to the Renilla signal. Results are the means + standard deviation (n = 3, * p < 0.05, ** p < 0.01). The 775 construct induced expression in this transient transfection assay. (C) The SERPINB2 eRNAs were mainly expressed in monocytes. The primary monocytes (M), T and B cells were purified from healthy people by Dynal bead purification and RNA was extracted and analyzed with qRT-PCR. Results were normalized to 18S expression (n = 3, error bars in panels denote SD). (D) The SERPINB2 eRNAs were localized primarily to the chromatin fraction. RNA was extracted from MonoMac6 cytoplasm, nucleoplasm, and chromatin fractions. PCR was performed after reverse transcription (n = 3, error bars in panels denote SD). Actin and HOTAIR are shown as positive controls for cytoplasmic and chromatin fractions, respectively. (E-G) Primary monocytes were purified by adherence and stimulated. RNA was harvested after 90 min of LPS treatment or LPS with the indicated inhibitors. SERPINB2 eRNAs (E), SERPINB2 mRNA (F), and SERPINB10 mRNA (G) were quantitated. Error bars are standard deviations (n = 3). The y-axis represents fold change over mock-treated cells(control). RNAs from the SERPINB2 Enhancer 1 region and the SERPINB2 mRNA were comparably regulated while SERPINB10 behaved differently.
higher in SLE patients (Fig. 1C) . These analyses support efforts to understand the regulatory dynamic of SERPINB2. It is the most highly upregulated gene in inflammatory bowel disease, strongly upregulated in SLE, and sequence variants are associated with multiple human diseases (Burczynski et al., 2006; Miao et al., 2013; Vazquez-Del Mercado et al., 2007; Palafox-Sanchez et al., 2009) . Our lack of understanding of the regulatory landscape is a significant knowledge gap.
The 774, 775 ncRNAs cluster in a single region with chromatin characteristics of an enhancer. 772 lies just at the distal edge of the enhancer chromatin. We tested the DNA corresponding to the 775 ncRNA in an enhancer assay by sub-cloning it downstream of a minimal thymidine kinase (TK) promoter. The DNA corresponding to the 775 ncRNA location was capable of augmenting luciferase production in this transient transfection assay in two different cell types (K562 and HEK293), thereby assigning it as a probable enhancer ( Fig. 2A and B) . For this reason, we will refer to the ncRNAs subsequently as eRNAs. Enhancer RNAs are predicted to have chromatin localization. To validate the remaining eRNAs, we used qRT-PCR from three different cell types to demonstrate tissue specificity and analyzed eRNA subcellular localization by fractionating cells. The eRNAs were found predominantly in monocytes and in the chromatin and nucleoplasm fractions predominantly (Fig. 2C and D) . This demonstration of enhancer activity of the DNA and chromatin localization support the assignment of the ncRNAs as eRNAs.
To understand the relationship of the RNAs to the various SERPIN family members, we treated primary monocytes with LPS and examined the effect on the ncRNAs and SERPIN family mRNAs, measured by qRT-PCR. We used a series of inhibitors to further characterize the regulation of expression of each of these RNAs. DRB is a CDK9 inhibitor, iBET targets bromodomains, C646 inhibits dynamic histone acetylation, SP600125 is a JNK inhibitor, U0126 is an MEK1/2 inhibitor, SB203580 is a p38-MAPK inhibitor and JSH-23 is an NFκB inhibitor. RNAs 772, 774, and 775 form a cluster 21 kb upstream of SERPINB2 in enhancerlike chromatin (Enhancer 1). Their pattern of expression closely paralleled that of SERPINB2 (Fig. 2E and F) but not SERPINB10 Fig. 3 . SERPINB2 eRNAs regulate transcription. (A) LPS-induced SERPINB2 RNA expression kinetic analysis. The eRNA and mRNA expression levels were measured using qRT-PCR at various time-points and normalized to 18S in MonoMac6 cells. SERPINB10 is minimally LPS-inducible while SERPINB2 responds to LPS. GAPDH is a non-inducible control. The eRNAs appear temporally before the mRNAs. (B) Knockdown of SERPINB2 eRNAs decreased the LPS-induced SERPINB2 mRNA. MonoMac6 cells were transfected with the indicated 20-bp phosphorothioate antisense oligonucleotides (ASO) designed to knock-down 774, 775 (two different ASO) or GFP for 3 h and stimulated with or without 1 μg/ml LPS for 60 min. The eRNAs and SERPINB2 mRNAs were measured using qRT-PCR. The antisense knock-down was specific and effective for each eRNA (left panel). SERPINB2 expression was inhibited while that of SERPINB10 (right panel) was not affected (n = 4, * p < 0.05, ** p < 0.01). (C) Over-expression of SERPINB2 eRNA led to increased SERPINB2 mRNA. The constructs pcDNA3.1 + (PC), pcDNA3.1-774 (PC-774) and pcDNA3.1-775 (PC-775) were the eRNA over-expression vectors and pcDNA3.1-477 (PC-477) was the off-target control. Constructs were transfected into MonoMac6 cells and stimulated with 1 μg/ml LPS for 60 min. Total RNA was isolated and qRT-PCR performed. The left panel confirms over-expression by the constructs while the right panel demonstrates that 774 and 775 overexpression drives increased SERPINB2 expression but not SERPINB10 expression. Results are the means with standard deviation (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001).
( Fig. 2G) . SERPINB10 is modestly LPS-inducible but not inhibitable. Thus, SERPINB2 exhibits a pattern consistent with that seen for the 772, 774 and 775 eRNAs. The 571 RNA, which lies near enhancer 2 but not within enhancer 2, had a slightly different pattern, with less induction by LPS. Based on comparable patterns of induction and inhibition, we tentatively assigned the 772, 774, and 775 RNAs to the SERPINB2 regulon.
We wished to define the kinetics of LPS induction of expression in Enhanceratlas.org tracks (accessed December 2016) display chromatin loops observed in CD14 monocytes at this locus, providing a three-dimensional framework for potential enhancerpromoter interactions (Gao et al., 2016) . Knock-down of 774 and 775 affected acquisition of H3K4me2 (C), H3K27ac (D), H3K4me3 (E), and H3K4me2 (F) at Enhancer 1 (left panels) and to a lesser degree extent at the promoter (middle panels) after LPS. The GAPDH promoter was not affected by LPS or the knock-downs (right panels). These experiments were performed in MonoMac6 cells (n = 4, * p < 0.05, ** p < 0.01).
our system. Expression of eRNAs typically precedes that of the target genes and eRNA expression is essential for function and parallels that of the target mRNA (Bose et al., 2017; Lai et al., 2013; Cheng et al., 2015) . Therefore, we performed careful kinetic analysis of eRNA and mRNA expression after LPS stimulation at early time points to define the order of transcript appearance. Expression of 772, 774 and 775 preceded SERPINB2 and SERPINB10 expression after LPS stimulation (Fig. 3A) . RNA 571 does not lie within an enhancer and SERPINB10 is not LPSinducible in MonoMac6 cells (in contrast to the slight inducibility seen in primary monocytes in Fig. 1 ), thus representing controls. 477 and 896 are eRNAs that are not LPS inducible and their expression is constant throughout the time course. GAPDH is a housekeeping gene not inducible with LPS. This kinetic analysis supports our definition of 772, 774, and 775 as eRNAs because their expression occurs temporally before SERPINB2 mRNA. The mechanistic role of eRNAs is incompletely understood and we therefore examined whether manipulation of eRNA levels in our system would modulate mRNA expression. 772 is located outside the peak of H3K27ac, demarking the limits of the enhancer. Therefore, we pursued a mechanistic analysis of 774 and 775. The 571 RNA is not thought to represent an eRNA based on chromatin characteristics and was not examined. We knocked down 774 and 775 as SERPINB2-specific eRNAs. Knock-down was validated by qRT-PCR of the target eRNAs. Knockdown of 774 and 775 led to inhibition of SERPINB2 mRNAs but not SERPINB10, which is not co-regulated with SERPINB2 (Fig. 3B ). An anti-sense oligonucleotide to GFP (AGFP) was used as an off-target control. Statistical analyses compared eRNA antisense treatment with GFP antisense treatment. We then over-expressed 774 and 775 to determine whether they could regulate SERPIN gene expression when provided in trans. Each over-expression construct was validated as expressing the correct RNA species (Fig. 3C) . Over-expression of both 774 and 775 led to higher SERPINB2 RNA but not the distinctly regulated SERPINB10. An off-target, control RNA, 477, had no effect. 477 is a ncRNA from a regulatory region at different locus that is not LPS inducible. Therefore, 774 and 775 appeared to be capable of regulating SERPINB2 expression.
Enhancer RNAs regulate target gene histone modifications
Enhancer RNAs have been hypothesized to regulate gene expression via diverse potential mechanisms. We tested whether they regulated histone modifications. To establish the landscape, we defined chromatin at the SERPINB2 locus using ChIP-seq from LPS-treated primary monocytes and control monocytes. LPS treatment led to increased H3K27ac at Enhancer 1 and increased H3K4me2 at both Enhancer 1 and promoter regions (Fig. 4A ). H3K27ac is a classic mark for enhancers and H3K4me2 is a mark that localizes to both promoters and enhancers. These data demonstrate the expected changes related to LPS stimulation. Fig. 4B demonstrates a CD14 monocyte track from enhanceratlas.org displaying chromatin loops between the enhancers and the promoter. To define effects related to eRNAs, we used antisense oligonucleotides to knock-down 774 and 775. We examined chromatin marks of gene activation in MonoMac6 cells at baseline and after treatment with LPS ( Fig. 4C-F) . We compared the effects of 774 and 775 knock-down with GFP knock-down. Non-transfected cells were included as assay controls for each experiment but are not shown to MonoMac6 cells were treated with 1 μg/ml LPS for the indicated time. ChIP assays were performed with antibodies to P-TEFb (CDK9) (A) or NELF-A (B). LPS led to increased CDK9 at the promoter and enhancer by 10 min and decreased NELF binding at the promoter and enhancer with slower kinetics (n = 4, * p < 0.05, ** p < 0.01). (C) Over-expression of 774 and 775 led to diminished NELF binding at the promoter even without LPS treatment. GAPDH is included as a non-LPS-inducible control and pc-DNA3.1 (PC) is a vector control. D) Knock-down of eRNAs did not alter the resting levels of NELF on the enhancer and promoter but there was a trend to preservation of NELF on DNA after LPS stimulation. GAPDH, in contrast, was unaffected by the knock-downs. streamline the figures. LPS was associated with increased H3K4me1, H3K4me2, H3K4me3 and H3K27ac at the SERPINB2 promoter and at Enhancer 1 (compare AGFP and LPS-GFP). The GAPDH promoter was unaffected by LPS stimulation and serves as a control. The anti-sense oligonucleotides to 774 and 775 were associated with diminished acquisition of the chromatin marks seen with LPS stimulation at Enhancer 1. The effect was limited to LPS-stimulated cells and was not observed in resting cells. Knock-down of 774 and 775 primarily affected H3K4me3 and H3K27ac at the promoter. These data demonstrate that eRNAs regulate histone modifications not just at the enhancer but also at their target gene promoter. In a model where chromatin looping is facilitated by eRNAs, chromatin modifying enzymes would be at the nexus of enhancer, eRNAs, transcription factors, and the promoter.
Enhancer RNAs regulate pause-release of RNAPII
An emerging mechanism by which eRNAs are thought to function involves binding to the NELF protein that regulates RNAPII pausing (Yamaguchi et al., 1999; Chiba et al., 2010) . To examine whether NELF and its major kinase are localized to the promoter and enhancer of SERPINB2, we performed ChIP studies for NELF and CDK9 (Fig. 5) . The goal was to define the presence of pause-release proteins on chromatin in unstimulated and stimulated settings. NELF in the paused state binds the nascent mRNA and RNAPII (Yamaguchi et al., 1999) . CDK9 is a component of P-TEFb, which phosphorylates NELF and RNAPII serine 2, releasing RNAPII from its paused state. At the SERPINB2 promoter and enhancer, CDK9 recruitment occurred rapidly after stimulation, peaking at 10 min (Fig. 5A) . Release of NELF from the promoter and enhancer was much slower (Fig. 5B) . GAPDH is a housekeeping gene, not regulated by pause-release, and neither CDK9 nor NELF were altered by stimulation at the GAPDH promoter. These data support an RNAPII pause-release mechanism regulating both SERPINB2 mRNA and eRNA transcription.
To define the effects of the eRNAs, we over-expressed 774 and 775 and treated cells with LPS. We hypothesized that the eRNAs would serve as a "sink" for NELF, leading to eviction from the promoter. LPS treatment was associated with loss of NELF at the enhancer and promoter (compare PC with LPS-PC), consistent with 5B. Over-expression of 774 and 775 led to diminished NELF at the promoter without LPS stimulation (Fig. 5C ). This suggested that one of the roles of the eRNAs might be in the modulation of NELF binding on chromatin. NELF binds the short mRNA produced by stalled RNAPII. We hypothesized that eRNAs can compete for NELF binding. Eviction of the pauseinducing NELF protein from the promoter of SERPINB2 would be expected to enhance elongation and increase transcript abundance, as was seen in Fig. 2 with 774 and 775 over-expression. We next performed the complementary experiment, knocking down the eRNAs (Fig. 5D) . Here, we saw relative preservation of NELF on DNA after LPS stimulation, although the results varied with different oligonucleotides.
We hypothesized that eRNA over-expression could compete for NELF binding, leading to dissociation from the nascent transcript. To further investigate the role of the eRNA, we defined RNA binding by NELF and CDK9 (Fig. 6) . We used RNA immunoprecipitation (RNA-IP) to define the enrichment of RNAs bound by NELF and CDK9 before and after LPS. In addition to the eRNAs, we quantitated binding of the stalled mRNA (B2 + 80), an irrelevant eRNA from another chromosome (896), and the promoter RNA species 571. After LPS, both CDK9 and NELF had greater association with the eRNAs but not the irrelevant RNA (896) from a regulatory region on another chromosome nor the upstream RNA, 571. Binding to the SERPINB2 stalled mRNA (B2 + 80) was minimally impacted by LPS stimulation supporting a specific interaction with eRNAs. CDK9 binding to eRNAs was coincident with the appearance on chromatin (Fig. 5A ) at 10 min of stimulation. In contrast, NELF bound the eRNAs at baseline with a gradual increase up to 30 min of stimulation. Eviction from chromatin, as detected by the ChIP assay, showed removal first detected at 30 min and progression at 60 min. Therefore, eRNA binding preceded eviction from chromatin. RNA-IP with antibodies to H4ac demonstrated that this complex was likely anchored to chromatin. These data place NELF and CDK9 engaging eRNAs on chromatin.
Histone modifications impact eRNA production
Our studies thus far focused on how eRNAs regulate SERPINB2 transcription. An equally important question is how eRNA expression itself is regulated. Fig. 2 demonstrated that LPS signaling pathway inhibitors could regulate eRNA expression supporting an overall transcription program comparable to that of mRNAs. C464, which inhibits de novo histone acetylation, DRB, which inhibits P-TEFb, and iBET, which inhibits bromodomain proteins were examined for their effects on LPS-inducible eRNA transcript abundance to define the role of chromatin in regulating eRNA expression. Each of the inhibitors targeted a distinct pathway. The inhibitors were associated with lower levels of SERPINB2 mRNA and eRNA abundance after LPS stimulation in primary monocytes (Fig. 7A-C) . SERPINB10, much less LPS induci- Fig. 6 . LPS induces CDK9 and NELF binding to the SERPINB2 eRNA. MonoMac6 cells were treated with 1 μg/ml LPS for 0, 10, 30 and 60 min. RNA-IPs were performed using NELF-A or CDK9 antibodies. Bound RNAs were detected by qRT-PCR. Input RNA was used for normalization. eRNAs were observed to significantly bind to CDK9 upon LPS stimulation with rapid kinetics. The effect was specific as neither the 896 nor 571 RNA species had significant induction of binding with LPS. The short mRNA, immediately downstream of the TSS (B2 + 80), exhibited a slight increase that did not reach significance. NELF, in contrast, bound eRNAs at baseline and increased binding after LPS, peaking at 30 min. The eRNAs remained associated with chromatin, as demonstrated by the H4ac RNA-IP. B2 + 80 is the first 80 nucleotides of the SERPINB2 mRNA and 896 is an off-target control RNA from a regulatory region that is not LPS inducible. 571 is from an upstream region of SERPINB2 that does nto appear to represent an enhancer. Results are the means + standard deviation (n = 3, * p < 0.05).
ble, exhibited a paradoxical increase with the inhibitors. These data suggest that the same chromatin modifications regulate eRNA and mRNA expression. Three MAP kinase inhibitors in Fig. 2 revealed a role for MAP kinases in regulating both eRNAs and mRNAs. We therefore examined whether eRNA over-expression altered c-JUN binding, a key transcription factor downstream of the MAP kinase pathway. Overexpression of 775 led to increased c-JUN binding at the enhancer but not at the promoter (Fig. 7D) . Accumulation of eRNAs may serve to recruit or stabilize transcription factors at enhancers.
Discussion
The precise physiologic function of SERPINB2 has been hotly debated because it is found predominantly as a 47 kDa cytosolic protein with minimal secretion as an extracellular glycosylated 60 kDa protein (Kruithof et al., 1995; Belin et al., 1989; Genton et al., 1987; Wohlwend et al., 1987) . Studies examining the function of SERPINB2 have focused on inflammation, malignancy and allergy (Kruithof et al., 1995; Darnell et al., 2006; Croucher et al., 2008; Gan et al., 1995; Antalis et al., 1998) . Its recently defined role in the misfolded protein response may tie together these disparate effects. Several studies have identified that overexpression of SERPINB2 protects from TNF-induced apoptosis (Kasyapa et al., 2006; Greten et al., 2007; Kumar and Baglioni, 1991; Dickinson et al., 1995) . In inflammatory disease, it may therefore offer a protective role.
Our data significantly increase our understanding of the regulation of SERPINB2 expression by demonstrating that pause-release of RNAPII is a key regulatory mechanism. This transcriptional regulatory strategy has been identified in approximately 30% of genes, however, it may be more common in genes involved in inflammatory responses (Core et al., 2008; Min et al., 2011) . In addition to identifying NELF and CDK9 (PTEFb) as key proteins interacting on the promoter, we identified an interaction between eRNAs and the pause-release machinery. This type of interaction has been infrequently described in detail. A recent study found that CBP, often found at enhancers, is activated by binding eRNAs and drives increased H3K27ac (Bose et al., 2017) . Enhancer RNAs have been previously described as luring NELF away from paused RNAPII at neuronal genes (Schaukowitch et al., 2014) . Other studies have focused on the biogenesis of eRNAs (Lai et al., 2015) . Yet, there is little consensus on the function of eRNAs even from the standpoint of Fig. 7 . The effect of chromatin inhibitors. Primary monocytes from healthy controls were pretreated with the 10 μM iBET (A), 40 μM DRB (B) or 20 μM C646 (C) for 30 min before adding 1 μg/ml LPS. Total RNA was isolated and qRT-PCR was used to measure the ncRNA or mRNA level (n = 4, error bars represent SD, * indicates p < 0.05, ** p < 0.01, *** p < 0.001). The y-axis represents fold change over untreated cells. Each inhibitor treatment was associated with diminished SERPINB2 mRNA as well as diminished levels of eRNAs. SERPINB10 mRNA levels were enhanced by inhibitor treatment, a paradoxical response. To define effects on transcription factor binding, eRNAs 774 and 775 were over-expressed and c-JUN binding was determined by ChIP-assay (D). 775 over-expression was associated with increased c-JUN at the enhancer. GST binding was unaffected (n = 3, error bars represent SD, * indicates p < 0.05).
chromosome looping with some studies supporting a role as facilitators of chromatin looping and others not (Lai et al., 2013; Hah et al., 2013; Hsieh et al., 2014) . One study suggested that eRNA expression and mRNA expression was not necessarily concordant at the single cell level (Rahman et al., 2017) . Therefore, there are key knowledge gaps in our understanding of enhancer function and eRNA function. This study is one of the first to provide detailed kinetic and binding analysis at a locus of specific medical interest.
NELF in the paused state binds a short mRNA tail and RNAPII. Our data support a model where the eRNAs compete for NELF binding, leading to release from pausing (Fig. 8) . A similar mechanism has been shown in HIV (Pagano et al., 2014; Sedore et al., 2007) . Our careful kinetic analysis allowed us to demonstrate that CDK9 recruitment to the promoter and NELF binding to the eRNAs preceded NELF eviction after LPS. This has important functional implications. It supports a model where eRNA binding is functionally relevant to release from pausing and regulated by an enhancer. In our model (Fig. 8) , P-TEFb (CDK9) appears on chromatin within 10 min of stimulation, coincident with CDK9 binding to eRNAs. A precondition for this in our current conceptualization is that P-TEFb has been liberated from 7SK snRNP through undefined mechanisms. P-TEFb is thought to dephosphorylate DSIF as part of liberation of NELF (Wada et al., 1998b) . Our data suggest that eRNA binding may replace 7SK snRNP binding for CDK9. In our model, eRNAs also bind to NELF as an intermediate step from 10 to 60 min after LPS stimulation followed by gradual liberation of NELF from the promoter. The first detectable increase in eRNA abundance is at 60 min post-stimulation followed by increased mRNA, first detected at 90 min post-stimulation. We hypothesize that the eRNA acts as a type of glue for this macromolecular interaction. Thus, over-expression of the eRNAs in trans can elicit chromatin effects and transcription factor binding by facilitating a favorable structure.
In spite of the great advances in our understanding of SERPINB2, this study does have some limitations. Our studies were performed primarily in MonoMac6 cells. Cell lines provide a homogeneous population for study, however, they often exhibit alterations to their epigenome as well as to chromosomal structure. A second limitation of this study is that we focused on a single stimulus, namely LPS. It may be that alternative stimuli utilize a different regulatory strategy. In spite of these limitations, our study has made a major contribution not only to the understanding of the regulation of SERPINB2 but also adds to the growing body of literature on the role of eRNAs at the promoter.
Conclusions
Our data suggest a model where the chromatin environment may favor eRNA expression and the eRNAs may serve to stabilize an architecture as well as preserve/induce a favorable histone landscape for transcription, although we have no direct data on this. Our data specifically demonstrate that the eRNAs can regulate histone modifications both at the enhancer and at the promoter. Manipulation of eRNA levels led to altered mRNA expression, altered interactions of pauserelease proteins on chromatin and even transcription factor binding. It is clear that transcription is not regulated according to a single paradigm, however, this study of SERPINB2 clearly expands our understanding of enhancer-promoter interactions and serves as a case-study for eRNA interactions with pause-release proteins.
Funding details
This work was supported by the Wallace Chair of Pediatrics and NIH grantR01AR058547. Fig. 8 . A model for SERPINB2 eRNA regulation of SERPINB2 transcription. In unstimulated cells, NELF binds the nascent mRNA and RNAPII. The SERPINB2 enhancer transcribes eRNAs after LPS treatment. These eRNAs regulate the histone modifications in the enhancer and promoter regions. The eRNAs interact with NELF and CDK9 (P-TEFb). P-TEFb phosphorylates NELF and RNAPII serine 2. Once released from NELF-induced pausing, RNAPII is able to enter into productive elongation and SERPINB2 mRNA is induced.
